Regeneron Pharmaceuticals Total Long Term Liabilities 2010-2024 | REGN

Regeneron Pharmaceuticals total long term liabilities for the quarter ending September 30, 2024 were $4.455B, a 21.71% increase year-over-year.

  • Regeneron Pharmaceuticals total long term liabilities for 2023 were $3.684B, a 8.05% increase from 2022.
  • Regeneron Pharmaceuticals total long term liabilities for 2022 were $3.409B, a 24.72% increase from 2021.
  • Regeneron Pharmaceuticals total long term liabilities for 2021 were $2.734B, a 20.55% decline from 2020.

Regeneron Pharmaceuticals Total Long Term Liabilities 2010-2024 | REGN

  • Regeneron Pharmaceuticals total long term liabilities for 2023 were $3.684B, a 8.05% increase from 2022.
  • Regeneron Pharmaceuticals total long term liabilities for 2022 were $3.409B, a 24.72% increase from 2021.
  • Regeneron Pharmaceuticals total long term liabilities for 2021 were $2.734B, a 20.55% decline from 2020.